Uncategorized

Is it harder to align with FDA expectations within pharma in 2026?  

Published

on

FDA headquarters

DDW Editor Reece Armstrong speaks to David Crean, Chief Business Officer of biopharmaceutical company MediciNova, about recent turmoil within the FDA and what the pharma sector should expect from the agency going forward. 

It’s been a volatile couple of years for the United States. President Trump’s second term has brought with it the kinds of government overreach, political divisiveness and impulsive behaviour that is shocking but not exactly surprising, once more onto the world stage.  

The life sciences sector is one such industry that hasn’t been able to avoid the turmoil brought by the President and Republican Party.  

Nowhere is this more evident than the staffing changes and multiple leadership-level exits that have consistently plagued the FDA in the last couple of years.  

Most notably, this year saw the resignation of FDA Commissioner Marty Markary as well as the second resignation of the Center for Biologics Evaluation and Research (CBER) Director Vinay Prasad. Before resigning, both of their tenures had been marked by some controversies, including a U-turn by the FDA on a decision regarding Moderna’s mRNA flu vaccine application and multiple rejections of rare diseases by Prasad’s CBER.  

There was also the unexpected result of Uniqure’s Phase I/II data for its Huntington’s Disease therapy not meeting the required evidence threshold – but more on that later.  

This is the context in which I start my conversation with Crean, who is keen to reflect upon both the positives and negatives of the FDA in current times and in fact likens the organisation’s problems to those of ambition versus execution.  

Crean, who has worked within the sector for over 30 years in various positions, states that the question of the FDA’s relationship with biotech is one he finds he nurses over often. In that time, he says that the actual structural relationship that the FDA has with biotech has improved a lot. 

He references examples such as breakthrough therapy designations and accelerated approvals, which have helped create a dialogue between pharma and the FDA to expedite the development of medicines. Crean even states how forward-looking the agency has been under Makary’s tenure, citing the FDA’s Plausible Mechanism Pathway, the integration of AI into the evaluation process, and the FDA’s draft guidance for ultra-rare diseases as being constructive moves by the agency.  

However, changes mentioned above such as those to staffing and cycling through of directors means that the execution of such strategies as well as the reliability of the FDA has been degraded in recent years.  

“I think there’s been, to my knowledge, no modern precedent in FDA history of going through five directors in 2025 alone and that list included Dr Richard Pazdur, a very well-respected agency veteran, of 26 years,” Crean shares as an example of the tenuous environment of the FDA over the last couple of years. 

In particular, Dr Pazdur’s resignation from the FDA is a great instance of how government can interfere with a scientific body which should by all accounts remain neutral to political beliefs. In a STAT News1, Dr Pazdur, who was the Director of the Centre for Drug Evaluation and Research (CDER) at the FDA, raised concerns with the amount of political interference that had to do with both regulatory decision-making but also the appointment of the staff who got to work at the FDA.   

These political influences aren’t subtle either. Anti-vaccine rhetorics made by the Health and Human Services Secretary Robert F. Kennedy Jr. highlight an agenda from the topmost level of the government.  

“I’m very much an advocate for science. That’s how I grew up. It put food on my table,” Crean says. “We’re seeing politics being drifted in, to be frank. It’s not the right thing to do.”  

This rhetoric now has been reflected in the policies put forward by the FDA. The FDA has moved towards introducing a new process for vaccine studies which demand more robust data and potentially longer trials – possibly delaying and restricting the number of vaccines that make it to market.  

The FDA has blocked the publication of studies showing that shingles vaccines and Covid-19 vaccines were safe, cut the number of routine vaccinations required by children, and has been undecided on vaccine approvals. For instance, the start of this year saw the FDA refuse to review Moderna’s mRNA-1010 flu vaccine, but recently an FDA panel agreed unanimously that the shot would bring benefits to patients, giving Moderna hope that mRNA-1010 could reach the market after all.  

Crean himself says he wouldn’t want to be working in vaccines at the moment.  

“It’s like they just don’t believe in it,” he says.  

An uncertain industry 

No industry likes uncertainty, least of all pharma. The constant influx of new directors and staff mean that agendas may never be fully set in stone.  

“Unfortunately, uncertainty has a dollar value associated with it from the standpoint of investors. It compresses valuations, it slows down capital deployment, and it forces drug developers to build conservative assumptions into the programmes that deserve more confidence,” Crean says.  

Crean states that Uniqure not meeting the required evidence threshold from the FDA, and requiring additional studies, is a perfect example of the agency’s indecisiveness affecting how a company can progress clinical trials.  

It must be said there are many things that could have impacted the FDA’s decision in this regard, whether that be a lack of transparency on the FDA’s part, a lack of due diligence by Uniqure, or a mixture of both. 

What’s more concerning are the changes we’ve seen introduced when new directors have come into the FDA – the turnaround of which has given the industry concerns over how best to conduct studies.  

Crean references the FDA’s decision to have developers of CAR-T therapies need an additional randomised control group study that shows greater efficacy than existing treatments. Previously, developers were only required to conduct a single-arm study without a control group. 

So, what can drug developers do to mitigate the risks of an uncertain regulatory body?  

“When we’re talking to investors, we talk about what we can control. Well, we can control the conduct of the clinical trial and execute it really well,” Crean says, also highlighting the importance of having interactions with the FDA on a very frequent periodic basis.”  

“Where we can’t control is if there’s a change in policy, or the lack of people at the agency, as I mentioned. That does create some uncertainty.”  

Moving forward   

Despite the turmoil that we’ve seen occur throughout the FDA under President Trump’s second term, Crean is still hopeful of genuine progress being made by the agency – especially when it comes to areas such as AI & new approach methodologies (NAMs) – but believes that the execution so far has been “deeply flawed”.  

Crean believes that the massive staff cuts that the FDA has undertaken has led to a lot of its “institutional knowledge” disappearing.  

I ask Crean if the FDA has largely played a reactionary role to introducing new policies for emerging technologies. Crean answered: “I’m not sure I would use the word reactionary. I think they’re thinking about it, but they’re significantly behind and creating more of a gap in terms of when to implement it. So, I would say that this FDA is not simply reactive, but it’s regulatory frameworks consistently lag behind the pace of technology adoption and that gap has only unfortunately widened.” 

“I don’t think they’re keeping up with the pace with which the industry has grown,” Crean says, giving the example of the emergence of computational chemistry in the 90s and how the FDA took several years to eventually introduce codified standards.  

What we’re seeing now is the FDA try to keep pace with the onslaught of AI. The difference is, according to Crean, that because so many people are using it, “the stakes are correspondingly larger.”  

So, what can the FDA be doing to make it easier for companies to work with AI for submissions, and where does the technology fit into the FDA’s own operations?  

“I think they could look at bringing in some liaison function on the AI side, to work with companies before they reach the submission stages,” Crean says.  

This could lead to frameworks that document implementation guidance, Crean advises. 

“Companies love concrete guidance so they love these checklists, not just principles. So, anything we can do around formal guidance are great. And then, frankly, I think with so much change at the agency they need to probably invest in reviewer training on AI tools and methodologies at a pace that is commensurate if you will, with the industry adoption. The industry is just way out in front on this aspect of AI technology. And so that’s what I would really like to see.” 

In terms of what the FDA can do itself to utilise AI, Crean believes that the technology could be used by the agency to help expedite the FDA’s drug review process.  

But like many people I’ve spoken to within the industry, Crean insists that “AI is not, that is not a tool or a technology that’s going to truly replace people. It’s going to help, it’ll make things more efficient. But at the end of the day, you still need human intelligence to go along with the AI intelligence. So, if you don’t have fundamentally someone there to accept an NDA review, or provide feedback as a project manager to the sponsor, that’s a problem.”  

Early-stage advice 

If there’s one key takeaway from my talk with Crean, it’s that engagement with the FDA is as crucial as ever – especially for early-stage company.  

“I think FDA engagement by early-stage biotech companies need not to be overlooked. It’s one of the most expensive mistakes that an early-stage company can make.”  

Crean details how during his time within the industry, he’s seen founding teams fill their ranks with world class scientists – “people who are really doing a lot of great stuff on the innovation and biology.”  

“They spend two to three years building up a very compelling story on a pre-clinical level, they go out and they try to raise money, and the biggest thing that they don’t do is go to the FDA and engage with them. That is, I think, a fundamental problem, because they should be getting that feedback from the FDA, whether that’s a validated biomarker as a primary outcome or maybe it’s a patient population that doesn’t really map to how the FDA is currently thinking about that disease.” 

Whilst it might seem sage, but fairly obvious advice, it is lacking in impact. If a company pursues a candidate without FDA engagement, and without understanding the correct clinical course, or where the obstacles lie, then the type of course correction can be costly and lengthy.  

A pre-IND meeting is then something that Crean states is “one of the most chronically underutilised tools in early-stage biotech.”  

As Crean says, “regulatory certainty, it’s a form of capital.”  

With the uncertainty that’s existed within the FDA recently, companies will be best served understanding this.  

References

1: https://www.statnews.com/2026/05/08/former-fda-regulators-on-why-they-left-status-report/

The post Is it harder to align with FDA expectations within pharma in 2026?   appeared first on Drug Discovery World (DDW).

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version